A rapid point-of-care test for the diagnosis of factor VIII inhibitors in hemophilia A patients
Journal of Thrombosis and Haemostasis · 2026-08 · 24 (8) · 2766-2778
DOI: 10.1016/j.jtha.2026.04.014 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift Journal of Thrombosis and Haemostasis, 2026-08. Verfasst von Shruti Kharat und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Haematology, K.J. Somaiya Hospital & Research Center, Somaiya Ayurvihar, Sion East, Mumbai, India. Hauptthemen laut MEDLINE: Hemophilia A, Factor VIII, Point-of-Care Testing, Antibodies, Neutralizing. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: Department of Biotechnology.
Abstract (Originalsprache)
BACKGROUND: The development of neutralizing antibodies or inhibitors against exogenous factor (F)VIII represents a major adverse event in hemophilia A treatment. The conventional assay for the diagnosis of FVIII inhibitors is the Nijmegen-modified Bethesda assay. This test is time-consuming, resource-intensive, and cost-prohibitive. The test lacks sensitivity and shows wide variation across quality surveys. OBJECTIVES: To develop a rapid, cost-effective, functionally relevant, sensitive, and specific test for FVIII inhibitors. METHODS: We developed and validated a cost-effective, accurate, and equipment-free point-of-care (POC) test for FVIII inhibitors in a paper-strip format using full-length recombinant FVIII and gold nanoparticle-labeled antibodies. RESULTS: The diagnostic sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of the FVIII inhibitor POC test were 0.93, 0.99, 0.94, 0.99, and 0.98, respectively, compared with the Nijmegen-modified Bethesda assay. The test was rapid (10 minutes), cost-effective (USD ≈$1-$1.5), equipment-free (naked-eye test), and required only a small volume (50 μL) of citrated whole blood or citrated plasma. The POC test was unaffected by nonneutralizing antibodies, residual FVIII, emicizumab, lupus anticoagulants, or heparin. CONCLUSION: The POC test shows promise as a valuable screening tool in resource-limited settings for timely diagnosis of FVIII inhibitors and can be applied even at the lowest tier of the health care system, where sophisticated equipment or technical expertise may not be available. With a turnaround time of 10 minutes, this POC test will be highly useful for timely clinical decision-making.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Haematology, K.J. Somaiya Hospital & Research Center, Somaiya Ayurvihar, Sion East, Mumbai, India.
- Department of Haematology, K.J. Somaiya Hospital & Research Center, Somaiya Ayurvihar, Sion East, Mumbai, India. Electronic address: shrimati@somaiya.edu.
Förderung
- Department of Biotechnology
Zitieren
APA
Kharat, S., Jivani, F., Patil, K., Saini, G. K., Dhawlarker, A., Bharankar, J., & Shetty, S. (2026). A rapid point-of-care test for the diagnosis of factor VIII inhibitors in hemophilia A patients. Journal of Thrombosis and Haemostasis, 24(8), 2766-2778. https://doi.org/10.1016/j.jtha.2026.04.014
Vancouver
Kharat S, Jivani F, Patil K, Saini GK, Dhawlarker A, Bharankar J, et al. A rapid point-of-care test for the diagnosis of factor VIII inhibitors in hemophilia A patients. Journal of Thrombosis and Haemostasis. 2026;24(8):2766-2778. doi:10.1016/j.jtha.2026.04.014
BibTeX
@article{Kharat2026,
author = {Kharat, Shruti and Jivani, Fiza and Patil, Kranti and Saini, Gurpreet Kaur and Dhawlarker, Anam and Bharankar, Juili and Shetty, Shrimati},
title = {A rapid point-of-care test for the diagnosis of factor VIII inhibitors in hemophilia A patients},
journal = {Journal of Thrombosis and Haemostasis},
year = {2026},
volume = {24},
number = {8},
pages = {2766--2778},
doi = {10.1016/j.jtha.2026.04.014}
}
EUVIMED